PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34103313-0	2021	Can 18F-FDG PET/CT predict EGFR status in patients with non-small cell lung cancer?	Fluorodeoxyglucose F18	4-11	epidermal growth factor receptor	Homo sapiens	27-31	
34103313-2	2021	OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC).	Fluorodeoxyglucose F18	71-93	epidermal growth factor receptor	Homo sapiens	173-205	
34103313-2	2021	OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC).	Fluorodeoxyglucose F18	71-93	epidermal growth factor receptor	Homo sapiens	207-211	
34103313-2	2021	OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC).	Fluorodeoxyglucose F18	95-102	epidermal growth factor receptor	Homo sapiens	173-205	
34103313-2	2021	OBJECTIVES: This study aimed to explore the diagnostic significance of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/CT for predicting the presence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC).	Fluorodeoxyglucose F18	95-102	epidermal growth factor receptor	Homo sapiens	207-211